Karyopharm Therapeutics (KPTI):Selinexor At ASH Could Drive Upside - Jefferies

Jefferies analyst, Brian Abrahams reiterated his Buy rating on shares of Karyopharm Therapeutics (NASDAQ: KPTI) and raised his price target to $14 thinking that a full presentation of its STORM and STOMP selinexor data -- as well as add'l data on selinexor in MM and AML, and next-gen '8602 -- could draw increasing attention to the activity and promise of its XPO1 inhibitor platform.

The analyst sees an opportunity for continued upside through and following ASH, which drives the PT up to $14 from $12.

For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.

Shares of Karyopharm Therapeutics closed at $9.03 yesterday.

You May Also Be Interested In

• LuxUrban Hotels Inc. (LUXH) PT Lowered to $4 at Jones Trading
• Alphabet (GOOGL) PT Raised to $174 at Stifel
• Morgan Stanley (MS) PT Raised to $108 at CFRA